Volume 1, Issue 4 (9-2025)
2025, 1(4): 14-19 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hematian A, Yazdanmanesh M, khosravi S, Ahmadi I, Gheitani L, Mahdian N et al . Clinical isolation and resistance patterns of Stenotrophomonas maltophilia in Ilam, Iran. Journal of Health Sciences Perspective 2025; 1 (4) :14-19
URL: http://jhsp.medilam.ac.ir/article-1-43-en.html
URL: http://jhsp.medilam.ac.ir/article-1-43-en.html
Ali Hematian 
, Mohammad Yazdanmanesh , Sina Khosravi , Iraj Ahmadi , Leila Gheitani , Nahid Mahdian , Maryam Karimi
, Mohammad Yazdanmanesh , Sina Khosravi , Iraj Ahmadi , Leila Gheitani , Nahid Mahdian , Maryam Karimi
Abstract: (27 Views)
Introduction: Stenotrophomonas maltophilia (SMA) is a commensal and an emerging nosocomial pathogen responsible for serious infections, especially in immunocompromised hosts. Its intrinsically multidrug-resistant bacteria to multiple antibiotics. Current study aimed to determine the antibiotic susceptibility patterns of SMA isolates from hospitalized patients in Ilam, Iran.
Materials & Methods: This cross-sectional study conducted between September 2022 and February 2023 in Ilam, Iran. Clinical specimens from 85 patients were cultured, and SMA isolates were identified through biochemical testing. Antimicrobial susceptibility testing performed using the disk diffusion method based on CLSI guidelines.
Results: Out of 85 samples, 10 (11.76%) isolates were identified as SMA. All isolates were susceptible to Co-trimoxazole (100%), and most were sensitive to Levofloxacin (90%). High resistance rates were observed toward Meropenem, Piperacillin/Tazobactam, Ceftriaxone (100% each), Cefepime (90%), Gentamicin (80%), Ceftazidime (90%), and Amikacin (60%). Our findings indicated the significant multidrug resistance profile of SMA in Ilam.
Conclusion: Continuous surveillance, strict infection control, better antimicrobial stewardship, enhanced research to develop, effective treatment and prevention strategies should be adopted to management the changing resistance profile of SMA.
Materials & Methods: This cross-sectional study conducted between September 2022 and February 2023 in Ilam, Iran. Clinical specimens from 85 patients were cultured, and SMA isolates were identified through biochemical testing. Antimicrobial susceptibility testing performed using the disk diffusion method based on CLSI guidelines.
Results: Out of 85 samples, 10 (11.76%) isolates were identified as SMA. All isolates were susceptible to Co-trimoxazole (100%), and most were sensitive to Levofloxacin (90%). High resistance rates were observed toward Meropenem, Piperacillin/Tazobactam, Ceftriaxone (100% each), Cefepime (90%), Gentamicin (80%), Ceftazidime (90%), and Amikacin (60%). Our findings indicated the significant multidrug resistance profile of SMA in Ilam.
Conclusion: Continuous surveillance, strict infection control, better antimicrobial stewardship, enhanced research to develop, effective treatment and prevention strategies should be adopted to management the changing resistance profile of SMA.
Keywords: Stenotrophomonas maltophilia, Antibiotic susceptibility patterns, Multidrug-resistant bacteria
Type of Study: Research |
Subject:
Healthcare setting
Received: 2025/07/6 | Accepted: 2025/08/30 | Published: 2025/09/22
Received: 2025/07/6 | Accepted: 2025/08/30 | Published: 2025/09/22
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |